^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NOUS-PEV
i
Other names: NOUS-PEV, NOUS PEV, NOUS-100-PV, Personalised cancer neoantigen genetic vaccine, GAd-PEV/MVA-PEV
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nouscom
Drug class:
Immunostimulant
Related drugs:
2ms
Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses. (PubMed, Clin Cancer Res)
These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor reactive T cells to empower a diverse, potent and durable antitumor immune response. Finally, a gene signature indicative for reduced presence of activated T cells together with very poor expression of the antigen processing machinery (APM) genes has been identified in pre-treatment biopsies as a potential biomarker of resistance to the treatment.
P1 data • Journal • PD(L)-1 Biomarker • Viral vector
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • NOUS-PEV
1year
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (clinicaltrials.gov)
P1b, N=34, Active, not recruiting, Nouscom SRL | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • NOUS-PEV
almost3years
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (clinicaltrials.gov)
P1b, N=34, Recruiting, Nouscom SRL
Clinical • New P1 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • NOUS-PEV
Share via
